Back
About the Global Fund
-
COVID-19 Urgent Mitigation Plan
- Our plan to mitigate the impact of COVID-19 on countries affected by HIV, TB and malaria
People & Structures
Funding Model
Investments & Results
-
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
- Data Explorer
- Funding Decisions
- Data Service
HIV & AIDS
Tuberculosis
MalariaNews
Updates
Stories
-
10 July 2020
Disruptions in HIV, TB and Malaria Programs due to COVID-19 -
10 July 2020
AIDS 2020: Fighting HIV in the Shadow of COVID-19 -
09 July 2020
Fighting HIV in India during COVID-19 -
07 July 2020
AIDS 2020: Going Forward in Partnership -
06 July 2020
Lifeline During Lockdown: Delivering Medicines During COVID-19 -
06 July 2020
We Cannot Go Backwards
Featured Publication
Documents by type
The Global Fund / Karin Schermbrucker
Withdrawal of the Quality Assurance Information Notice 2016-02 regarding IPCA Ratlam Manufacturing Site
15 July 2019
The Quality Assurance Information Notice 2016-02 providing recommendations regarding the procurement and the distribution of finished pharmaceutical products using active pharmaceutical ingredients manufactured at IPCA Ratlam Manufacturing Site is withdrawn. This is to reflect the Sourcing and Supply Chain Department decision that no specific quality assurance requirements are currently implemented by Global Fund quality assurance on IPCA finished pharmaceuticals products.
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.